Exclusive Online Content
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Absci Enters Multi-Program Collaboration With Emerging Biotech Partner
Absci Corporation recently announced it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by….
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase 3 Part A Clinical Trial
Akari Therapeutics, Plc recently announced a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase 3 Part A clinical trial in pediatric hematopoietic stem….
Insilico Medicine Identified Multiple New Targets for ALS Using its AI-Driven Target Discovery Engine
Insilico Medicine recently announced the company has identified multiple unreported potential therapeutic targets for amyotrophic lateral sclerosis (ALS), using its proprietary AI-driven target discovery engine….
Alvotech Initiates Patient Study for Proposed Biosimilar for Eylea
Alvotech recently announced the initiation of the company’s confirmatory clinical study for AVT06 (aflibercept), a biosimilar candidate to Eylea…..
Mogrify & Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss
Mogrify Limited and Astellas Pharma Inc. recently announced they have executed a collaborative research agreement on in vivo regenerative medicine approaches to….
Codiak BioSciences & CEPI Partner to Develop Broadly Protective Betacoronavirus Vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences recently announced the latest funding award under CEPI’s US $200 million program to advance the development of vaccines that provide broad protection against….
DFE Pharma Expands its Inhalation Portfolio With New Launch
DFE Pharma recently announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation-grade lactose…..
BriaCell Partners With Waisman Biomanufacturing to Manufacture & Supply Prostate Cancer Immunotherapy
BriaCell Therapeutics Corp. has recently entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros, BriaCell’s off-the-shelf personalized….
Cara Therapeutics Announces Positive Topline Results From Phase 2 Trial of Oral Difelikefalin
Cara Therapeutics, Inc. recently announced positive topline results from its Phase 2 proof-of-concept clinical trial (KOMFORT) evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in….
US Government to Support Expansion of Croda Lipid Systems Capability
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
Neurona Therapeutics recently announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study…..
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 Therapeutics, Inc. recently announced it has screened its first patient in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex…..
Norstella & Citeline Unite to Offer Life Sciences Clients a Full Suite of Commercial & Clinical Solutions
Norstella and Citeline (formerly Pharma Intelligence) have recently announced an agreement to merge the companies. By uniting Norstella, which is composed of four prominent pharmaceutical solutions providers….
Terumo Blood and Cell Technologies & GenCure Collaborate to Advance Cell & Gene Therapy Manufacturing Solutions
Terumo Blood and Cell Technologies recently announced it has signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions…..
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration With ONO Pharmaceutical
Fate Therapeutics, Inc. recently announced it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. to include the development of….
Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills
With the realization of the first successful customer fills, Vetter has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned,….
Cullinan Oncology & Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop & Commercialize CLN-081/TAS6417
Cullinan Oncology, Inc. recently announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022. Per the terms of the agreement….
Silo Pharma Expands License Agreement & Patent Portfolio
Silo Pharma, Inc. recently announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting….
Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….
